Literature DB >> 15026115

Intraparenchymal nerve growth factor improves behavioral deficits while minimizing the adverse effects of intracerebroventricular delivery.

D P Pizzo1, L J Thal.   

Abstract

Nerve growth factor (NGF) delivered via intracerebroventricular (ICV) infusion restores behavioral and biochemical deficits in animal models of cholinergic hypofunction. However, ICV infusion of NGF induces an array of adverse events including weight loss, thermal hyperalgesia, and Schwann cell hyperplasia. We compared ICV administration with three different doses of intraparenchymally delivered NGF with cytochrome C infusion serving as a control. The goal of the study was to determine whether direct infusion of NGF would result in a more restricted topographical distribution of NGF leading to a reduction or elimination of the adverse events while still augmenting cholinergic functioning sufficiently to restore spatial mnemonic processing. Subsequent to bilateral ibotenic acid lesions of the nucleus basalis magnocellularis (NBM), NGF was delivered into the lateral ventricle or adjacent to the NBM for 11 weeks. Ibotenic acid lesions resulted in reductions in choline acetyltransferase (ChAT) activity in the cortex. The highest and medium dose of NGF led to significant restoration in ChAT activity on par with ICV infusion. The lowest dose was ineffective in altering ChAT activity in any region assayed. Similarly, the two highest doses did not alter weight gain, but ICV-NGF led to a significant weight loss. Intraparenchymal infusion resulted in a dose-dependent attenuation of the development of thermal hyperalgesia. However, the highest dose of intraparenchymal NGF induced Schwann cell hyperplasia at the level of the medulla and upper cervical spinal cord. ICV-NGF was able to completely restore spatial learning and memory as predicted while only the highest intraparenchymal dose was able to able to restore the mnemonic deficits. These data suggest that intraparenchymal infusion of growth factors may provide a viable delivery method in clinical trials using this mode of drug delivery once an optimal dose has been established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026115     DOI: 10.1016/j.neuroscience.2003.12.041

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Recombinant expression of human nerve growth factor beta in rabbit bone marrow mesenchymal stem cells.

Authors:  Bo-Sheng Fan; Ji-Yu Lou
Journal:  Mol Biol Rep       Date:  2010-03-17       Impact factor: 2.316

2.  Effects of nerve growth factor in experimental model of focal microgyria.

Authors:  Antonio Chiaretti; Alessandro Narducci; Federica Novegno; Alessia Antonelli; Filomena Pierri; Claudia Fantacci; Concezio Di Rocco; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2011-07-01       Impact factor: 1.475

3.  Widespread cortical expression of MANF by AAV serotype 7: localization and protection against ischemic brain injury.

Authors:  Mikko Airavaara; Matt J Chiocco; Doug B Howard; Katie L Zuchowski; Johan Peränen; Chao Liu; Shengyun Fang; Barry J Hoffer; Yun Wang; Brandon K Harvey
Journal:  Exp Neurol       Date:  2010-06-02       Impact factor: 5.330

4.  Age-related changes of NGF, BDNF, parvalbumin and neuronal nitric oxide synthase immunoreactivity in the mouse hippocampal CA1 sector.

Authors:  Natsumi Hayakawa; Manami Abe; Risa Eto; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2008-04-18       Impact factor: 3.584

5.  Dimethyl fumarate improves cognitive impairment by enhancing hippocampal brain-derived neurotrophic factor levels in hypothyroid rats.

Authors:  Haiyan Pan; Yanbo Wang; Xiaowei Wang; Ci Yan
Journal:  BMC Endocr Disord       Date:  2022-07-22       Impact factor: 3.263

6.  Intracerebroventricular administration of nerve growth factor induces gliogenesis in sensory ganglia, dorsal root, and within the dorsal root entry zone.

Authors:  Johannes C M Schlachetzki; Donald P Pizzo; Debbi A Morrissette; Jürgen Winkler
Journal:  Biomed Res Int       Date:  2014-03-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.